Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Income (2021 - 2025)

Historic Net Income for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' Net Income rose 11783.95% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 7733.19%. This contributed to the annual value of -$140.0 million for FY2024, which is 4657.85% up from last year.
  • Arcutis Biotherapeutics' Net Income amounted to $7.4 million in Q3 2025, which was up 11783.95% from -$15.9 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Net Income ranged from a high of $7.4 million in Q3 2025 and a low of -$107.7 million during Q3 2022
  • In the last 5 years, Arcutis Biotherapeutics' Net Income had a median value of -$52.3 million in 2024 and averaged -$50.2 million.
  • In the last 5 years, Arcutis Biotherapeutics' Net Income crashed by 8870.49% in 2022 and then skyrocketed by 11783.95% in 2025.
  • Quarter analysis of 5 years shows Arcutis Biotherapeutics' Net Income stood at -$71.3 million in 2021, then fell by 1.03% to -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then surged by 83.72% to -$10.8 million in 2024, then skyrocketed by 168.69% to $7.4 million in 2025.
  • Its Net Income was $7.4 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$25.1 million in Q1 2025.